A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms.
Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Pemmaraju N, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal R, Pierce S, Meyer M, Huang X, Garcia-Manero G.
Bouligny IM, et al.
Leukemia. 2024 Nov 17. doi: 10.1038/s41375-024-02457-7. Online ahead of print.
Leukemia. 2024.
PMID: 39551874
No abstract available.